Please use this identifier to cite or link to this item:
https://doi.org/10.1186/1479-5876-10-121
DC Field | Value | |
---|---|---|
dc.title | Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis | |
dc.contributor.author | Malek, J.A | |
dc.contributor.author | Martinez, A | |
dc.contributor.author | Mery, E | |
dc.contributor.author | Ferron, G | |
dc.contributor.author | Huang, R | |
dc.contributor.author | Raynaud, C | |
dc.contributor.author | Jouve, E | |
dc.contributor.author | Thiery, J.-P | |
dc.contributor.author | Querleu, D | |
dc.contributor.author | Rafii, A | |
dc.date.accessioned | 2020-10-27T11:27:39Z | |
dc.date.available | 2020-10-27T11:27:39Z | |
dc.date.issued | 2012 | |
dc.identifier.citation | Malek, J.A, Martinez, A, Mery, E, Ferron, G, Huang, R, Raynaud, C, Jouve, E, Thiery, J.-P, Querleu, D, Rafii, A (2012). Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis. Journal of Translational Medicine 10 (1) : 121. ScholarBank@NUS Repository. https://doi.org/10.1186/1479-5876-10-121 | |
dc.identifier.issn | 14795876 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/181608 | |
dc.description.abstract | Background: Ovarian cancer is the most deadly gynecological cancer due to late diagnosis at advanced stage with major peritoneal involvement. To date most research has focused on primary tumor. However the prognosis is directly related to residual disease at the end of the treatment. Therefore it is mandatory to focus and study the biology of meatastatic disease that is most frequently localized to the peritoneal caivty in ovarian cancer.Methods: We used high-density gene expression arrays to investigate gene expression changes between matched primary and metastatic (peritoneal) lesions.Results: Here we show that gene expression profiles in peritoneal metastasis are significantly different than their matched primary tumor and these changes are affected by underlying copy number variation differences among other causes. We show that differentially expressed genes are enriched in specific pathways including JAK/STAT pathway, cytokine signaling and other immune related pathways. We show that underlying copy number variations significantly affect gene expression. Indeed patients with important differences in copy number variation displayed greater gene expression differences between their primary and matched metastatic lesions.Conclusions: Our analysis shows a very specific targeting at both the genomic and transcriptomic level to upregulate certain pathways in the peritoneal metastasis of ovarian cancer. Moreover, while primary tumors use certain pathways we identify distinct differences with metastatic lesions. The variation between primary and metastatic lesions should be considered in personalized treatment of ovarian cancer. © 2012 Malek et al.; licensee BioMed Central Ltd. | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | Unpaywall 20201031 | |
dc.subject | 1 (1 cyano 1 methylethyl) 3 methyl 8 (3 quinolinyl)imidazo[4,5 c]quinolin 2(1h,3h) one | |
dc.subject | 4 diallylaminomethylene 1,3,4,7,10,11,12,13,14,15,16,17 dodecahydro 6 hydroxy 1 methoxymethyl 10,13 dimethyl 3,7,17 trioxo 2 oxacyclopenta[a]phenanthren 11 yl acetate | |
dc.subject | [1 (4 oxo 8 phenyl 4h 1 benzopyran 2 yl)morpholinio]methoxysuccinylarginylglycylaspartylserine acetate | |
dc.subject | buparlisib | |
dc.subject | carboplatin | |
dc.subject | crizotinib | |
dc.subject | DNA | |
dc.subject | interleukin 6 | |
dc.subject | Janus kinase | |
dc.subject | mitogen activated protein kinase kinase kinase 4 | |
dc.subject | paclitaxel | |
dc.subject | phosphatidylinositol 3 kinase | |
dc.subject | RNA | |
dc.subject | STAT protein | |
dc.subject | tocilizumab | |
dc.subject | vemurafenib | |
dc.subject | xl 147 | |
dc.subject | adjuvant therapy | |
dc.subject | article | |
dc.subject | clinical article | |
dc.subject | copy number variation | |
dc.subject | enzyme activation | |
dc.subject | enzyme inhibition | |
dc.subject | female | |
dc.subject | gene expression | |
dc.subject | gene expression profiling | |
dc.subject | gene targeting | |
dc.subject | haplotype map | |
dc.subject | human | |
dc.subject | human tissue | |
dc.subject | immune response | |
dc.subject | multiple cycle treatment | |
dc.subject | nucleotide sequence | |
dc.subject | ovary cancer | |
dc.subject | peritoneum metastasis | |
dc.subject | personalized medicine | |
dc.subject | signal transduction | |
dc.subject | transcriptomics | |
dc.subject | Female | |
dc.subject | Gene Expression Profiling | |
dc.subject | Humans | |
dc.subject | Ovarian Neoplasms | |
dc.subject | Peritoneal Neoplasms | |
dc.subject | Prognosis | |
dc.type | Article | |
dc.contributor.department | CANCER SCIENCE INSTITUTE OF SINGAPORE | |
dc.description.doi | 10.1186/1479-5876-10-121 | |
dc.description.sourcetitle | Journal of Translational Medicine | |
dc.description.volume | 10 | |
dc.description.issue | 1 | |
dc.description.page | 121 | |
Appears in Collections: | Elements Staff Publications |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1186_1479-5876-10-121.pdf | 2.51 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License